On August 24, 2015, the Patent Trial and Appeal Board declined institution of two petitions filed by Coalition For Affordable Drugs for Inter Partes Reviews of Acorda's patents covering Ampyra, a billion-dollar drug for treating multiple sclerosis. The Petitioner, Coalition For Affordable Drugs, is a wholly owned subsidiary of a hedge fund managed by Kyle Bass, which appears to have little to do with the life science and drug industry other than filing IPR petitions against patents owned by pharmaceutical and biotechnology companies.